Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Inv. presentation
Cert. of designation
Quarterly results
Acq. announced
HARROW HEALTH, INC. (IMMY) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF HARROW, INC. dated as of September 29, 2023",
"Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. NASHVILLE, Tenn., September 29, 2023 – Harrow , a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health, Inc.” to “Harrow, Inc.” to align with the Company’ s current five-year strategic plan, which includes an exclusive focus on eyecare pharmaceuticals. “Given the growing recognition of the Harrow name within the ophthalmic community, along with the connection of the Harrow brand to what is now one of the largest portfolios of ophthalmic pharmaceutical products in the U.S. market, we believed it was the right time to represent our exclusive commitment to the ophthalmic market by shortening our corporate name to Harrow, Inc.,” said Mark L. Baum, Chief Execu..."
08/18/2023 SC 13D/A BAUM MARK L reports a 9.5% stake in HARROW HEALTH, INC.
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Harrow Announces Second Quarter 2023 Financial Results Second Quarter 2023 and Recent Selected Highlights:",
"GAAP Operating Results"
07/21/2023 8-K Quarterly results
07/19/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/18/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/18/2023 8-K Quarterly results
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Harrow Announces First Quarter 2023 Financial Results First Quarter 2023 and Recent Selected Highlights:",
"Letter to Stockholders May 11, 2023 Dear Harrow Stockholders: I am pleased to report that the Harrow team delivered record revenues of $26.1 million for the first quarter of 2023. Even more important than this strong sequential topline growth is that we have now entered a new revenue paradigm for Harrow from which we expect revenue growth from our branded pharmaceutical products to meaningfully outpace growth from our compounded pharmaceutical products , with revenue from branded products ultimately driving the lion’ s share of our future profitability and topline growth. Simply put, with the addition of a powerful portfolio of branded and reimbursable products “in our bag,” we are now beginning to experience financial leverage from the many years of hard work invested in building our comm..."
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/28/2023 8-K Quarterly results
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "Harrow Announces Fourth Quarter and Year-End 2022 Financial Results 2022 and Recent Highlights:",
"Letter to Stockholders March 23, 2023 Dear Harrow Stockholders: Let me begin with some highlights regarding your Harrow stockholdings."
01/23/2023 8-K Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits  Interact...
Docs: "Harrow Closes Acquisition of U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE and Will Begin Receiving Net Profit Payments for Acquired Products",
"UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET The accompanying unaudited pro forma condensed consolidated balance sheet for Harrow Health, Inc. and subsidiaries as of September 30, 2022 gives effect to the following transactions: the cash received by the Company in connection with the Company’ s sale and divestment of its non-ophthalmology related compounding revenue line and related intangible assets, and the net gain on sale; the net proceeds from the sale of 2,376,426 shares of the Company’ s common stock, at a price of $10.52 per share, after deducting underwriting discounts and commissions, structuring and commitment fees, and estimated offering expenses payable by the Company; the net proceeds from the sale of $40,250,000 aggregate principal amount of 11.875% senior unsecu..."
01/20/2023 SC 13G/A Opaleye Management Inc. reports a 12.8% stake in HARROW HEALTH, INC.
01/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Letter re: Harrow Health, Inc."
12/20/2022 CERT Form CERT - Certification by an exchange approving securities for listing:
12/20/2022 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
12/20/2022 8-K Quarterly results
12/19/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/16/2022 305B2 Form 305B2 - Filing [Trust Indenture Act]:
12/16/2022 8-K Quarterly results
12/16/2022 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
12/14/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/14/2022 8-K Quarterly results
12/14/2022 8-K Quarterly results
12/14/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
10/11/2022 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
10/05/2022 8-K Quarterly results
09/22/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy